Accu-Break and Midas Pharma agree terms for drug promotion

A European cooperation agreement between Accu-Break Pharmaceuticals (ABP) and Midas Pharma is hoped to broaden licensing opportunities for ABP's technologies.

The parties will work together to both license the Accu-Break technologies to European brand and generic pharmaceutical companies, and develop and market ABP products in Europe.

Midas will help ABP introduce, market and promote the Accu-Break technologies to potential collaboration partners. The company will also help ABP prepare regulatory information and in communications with health authorities and European opinion leaders to promote the licensing of the Accu-Break technologies.

Allan S. Kaplan ABP's ceo, said: "This agreement with Midas will help broaden the opportunities available to ABP to license the patented and patent pending Accu-Break Technologies worldwide."

"ABP and Midas have been working together for a number of months and we are delighted to have formalised this relationship," said Nigel Norton, ABP executive director who leads ABP's international business development group, based in Monaco. "Through Midas, ABP has already been introduced to a number of interested companies, which we hope will result in licensing agreements. We look forward to continuing and further developing our relationship with Midas."